CARs on track in the clinic.
作者信息
Kohn Donald B, Dotti Gianpietro, Brentjens Renier, Savoldo Barbara, Jensen Michael, Cooper Laurence Jn, June Carl H, Rosenberg Steven, Sadelain Michel, Heslop Helen E
机构信息
Department of Microbiology, Immunology, and Molecular Genetics, University of California, Los Angeles, Los Angeles, California 90095, USA.
出版信息
Mol Ther. 2011 Mar;19(3):432-8. doi: 10.1038/mt.2011.1.
Abstract
摘要
相似文献
1
CARs on track in the clinic.嵌合抗原受体在临床中步入正轨。
Mol Ther. 2011 Mar;19(3):432-8. doi: 10.1038/mt.2011.1.
2
Gene-modified hematopoietic stem cells for cancer immunotherapy.用于癌症免疫治疗的基因修饰造血干细胞
Hum Vaccin Immunother. 2014;10(4):982-5. doi: 10.4161/hv.27637. Epub 2014 Jan 9.
3
Immunotherapy with chimeric antigen receptors for multiple myeloma.用于多发性骨髓瘤的嵌合抗原受体免疫疗法。
Discov Med. 2014 Jan;17(91):37-46.
4
Modification of hematopoietic stem/progenitor cells with CD19-specific chimeric antigen receptors as a novel approach for cancer immunotherapy.用 CD19 特异性嵌合抗原受体修饰造血干细胞/祖细胞作为癌症免疫治疗的新方法。
Hum Gene Ther. 2013 Oct;24(10):824-39. doi: 10.1089/hum.2012.202.
5
Do CARs need a driver's license? Adoptive cell therapy with chimeric antigen receptor-redirected T cells has caused serious adverse events.嵌合抗原受体（CAR）疗法需要驾驶执照吗？采用嵌合抗原受体重定向T细胞的过继性细胞疗法已引发严重不良事件。
Hum Gene Ther. 2010 Sep;21(9):1039-42. doi: 10.1089/hum.2010.131.
6
7
HIV-1-Specific Chimeric Antigen Receptors Based on Broadly Neutralizing Antibodies.基于广泛中和抗体的HIV-1特异性嵌合抗原受体
J Virol. 2016 Jul 11;90(15):6999-7006. doi: 10.1128/JVI.00805-16. Print 2016 Aug 1.
8
Antibody-modified T cells: CARs take the front seat for hematologic malignancies.抗体修饰的 T 细胞：CARs 在血液恶性肿瘤中占据主导地位。
Blood. 2014 Apr 24;123(17):2625-35. doi: 10.1182/blood-2013-11-492231. Epub 2014 Feb 27.
9
The pharmacology of second-generation chimeric antigen receptors.第二代嵌合抗原受体的药理学
Nat Rev Drug Discov. 2015 Jul;14(7):499-509. doi: 10.1038/nrd4597.
10
Evaluation of Intracellular Signaling Downstream Chimeric Antigen Receptors.嵌合抗原受体下游细胞内信号传导的评估
PLoS One. 2015 Dec 23;10(12):e0144787. doi: 10.1371/journal.pone.0144787. eCollection 2015.
引用本文的文献
1
Zebrafish as a Model for Translational Immuno-Oncology.斑马鱼作为转化免疫肿瘤学的模型
J Pers Med. 2025 Jul 11;15(7):304. doi: 10.3390/jpm15070304.
2
CAR-T cell therapy for cancer: current challenges and future directions.用于癌症治疗的嵌合抗原受体T细胞疗法：当前挑战与未来方向
Signal Transduct Target Ther. 2025 Jul 4;10(1):210. doi: 10.1038/s41392-025-02269-w.
3
Significant Advancements and Evolutions in Chimeric Antigen Receptor Design.嵌合抗原受体设计的重大进展和演变。
Int J Mol Sci. 2024 Nov 13;25(22):12201. doi: 10.3390/ijms252212201.
4
Effectiveness and Safety of Anti-CD19 Chimeric Antigen Receptor-T Cell Immunotherapy in Patients With Relapsed/Refractory Large B-Cell Lymphoma: A Systematic Review and Meta-Analysis.抗CD19嵌合抗原受体T细胞免疫疗法治疗复发/难治性大B细胞淋巴瘤患者的有效性和安全性：一项系统评价和荟萃分析
Front Pharmacol. 2022 Apr 25;13:834113. doi: 10.3389/fphar.2022.834113. eCollection 2022.
5
Proceedings From the First International Workshop at Sidra Medicine: "Engineered Immune Cells in Cancer Immunotherapy (EICCI): From Discovery to Off-the-Shelf Development", 15-16 February 2019, Doha, Qatar.第一届锡德拉医学国际研讨会会议记录：“癌症免疫治疗中的工程化免疫细胞（EICCI）：从发现到现成产品开发”，2019 年 2 月 15-16 日，卡塔尔多哈。
Front Immunol. 2021 Jan 14;11:589381. doi: 10.3389/fimmu.2020.589381. eCollection 2020.
6
Development of GPC3 and EGFR-dual-targeting chimeric antigen receptor-T cells for adoptive T cell therapy.用于过继性T细胞治疗的GPC3和EGFR双靶点嵌合抗原受体T细胞的开发
Am J Transl Res. 2021 Jan 15;13(1):156-167. eCollection 2021.
7
SITC cancer immunotherapy resource document: a compass in the land of biomarker discovery.SITC 癌症免疫治疗资源文件：生物标志物发现领域的指南针。
J Immunother Cancer. 2020 Dec;8(2). doi: 10.1136/jitc-2020-000705.
8
Cancer Immunotherapy Using Chimeric Antigen Receptor Expressing T-Cells: Present and Future Needs of Clinical Cancer Centers.嵌合抗原受体表达 T 细胞的癌症免疫治疗：临床癌症中心的现在和未来需求。
Front Immunol. 2020 Oct 30;11:565236. doi: 10.3389/fimmu.2020.565236. eCollection 2020.
9
Less is more: reducing the number of administered chimeric antigen receptor T cells in a mouse model using a mathematically guided approach.少即是多：使用数学指导方法减少小鼠模型中给予的嵌合抗原受体 T 细胞数量。
Cancer Immunol Immunother. 2020 Jul;69(7):1165-1175. doi: 10.1007/s00262-020-02516-9. Epub 2020 Mar 4.
10
The Cross Talk between Cancer Stem Cells/Cancer Initiating Cells and Tumor Microenvironment: The Missing Piece of the Puzzle for the Efficient Targeting of these Cells with Immunotherapy.癌症干细胞/癌症起始细胞与肿瘤微环境之间的相互作用：免疫疗法有效靶向这些细胞的关键缺失环节。
Cancer Microenviron. 2019 Dec;12(2-3):133-148. doi: 10.1007/s12307-019-00233-1. Epub 2019 Nov 22.
本文引用的文献
1
Immune responses to transgene and retroviral vector in patients treated with ex vivo-engineered T cells.经体外工程化 T 细胞治疗的患者对转基因和逆转录病毒载体的免疫反应。
Blood. 2011 Jan 6;117(1):72-82. doi: 10.1182/blood-2010-07-294520. Epub 2010 Oct 1.
2
Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19.自体 T 细胞经基因工程改造后识别 CD19，用于治疗患者，可消除 B 细胞系细胞并使淋巴瘤消退。
Blood. 2010 Nov 18;116(20):4099-102. doi: 10.1182/blood-2010-04-281931. Epub 2010 Jul 28.
3
Adoptive immunotherapy with genetically engineered T cells: modification of the IgG1 Fc 'spacer' domain in the extracellular moiety of chimeric antigen receptors avoids 'off-target' activation and unintended initiation of an innate immune response.采用基因工程 T 细胞的过继免疫疗法：嵌合抗原受体细胞外部分的 IgG1 Fc“间隔区”结构域的修饰可避免“脱靶”激活和非预期固有免疫反应的启动。
Gene Ther. 2010 Oct;17(10):1206-13. doi: 10.1038/gt.2010.91. Epub 2010 Jun 17.
4
Redirecting T-cell specificity by introducing a tumor-specific chimeric antigen receptor.通过引入肿瘤特异性嵌合抗原受体来改变 T 细胞的特异性。
Blood. 2010 Aug 19;116(7):1035-44. doi: 10.1182/blood-2010-01-043737. Epub 2010 May 3.
5
Engineering CD19-specific T lymphocytes with interleukin-15 and a suicide gene to enhance their anti-lymphoma/leukemia effects and safety.用白细胞介素 15 和自杀基因工程改造 CD19 特异性 T 淋巴细胞，以增强其抗淋巴瘤/白血病效应和安全性。
Leukemia. 2010 Jun;24(6):1160-70. doi: 10.1038/leu.2010.75. Epub 2010 Apr 29.
6
Treatment of chronic lymphocytic leukemia with genetically targeted autologous T cells: case report of an unforeseen adverse event in a phase I clinical trial.采用基因靶向自体T细胞治疗慢性淋巴细胞白血病：一项I期临床试验中意外不良事件的病例报告
Mol Ther. 2010 Apr;18(4):666-8. doi: 10.1038/mt.2010.31.
7
Safer CARS.更安全的汽车碰撞减速度限制系统（CARS）
Mol Ther. 2010 Apr;18(4):661-2. doi: 10.1038/mt.2010.42.
8
Antitransgene rejection responses contribute to attenuated persistence of adoptively transferred CD20/CD19-specific chimeric antigen receptor redirected T cells in humans.抗转基因排斥反应导致过继转移的 CD20/CD19 特异性嵌合抗原受体重定向 T 细胞在人体内的持久性减弱。
Biol Blood Marrow Transplant. 2010 Sep;16(9):1245-56. doi: 10.1016/j.bbmt.2010.03.014. Epub 2010 Mar 19.
9
Building better chimeric antigen receptors for adoptive T cell therapy.构建更好的嵌合抗原受体用于过继性 T 细胞疗法。
Curr Gene Ther. 2010 Apr;10(2):77-90. doi: 10.2174/156652310791111001.
10
Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2.嵌合抗原受体识别 ERBB2 的 T 细胞给药后严重不良事件的病例报告。
Mol Ther. 2010 Apr;18(4):843-51. doi: 10.1038/mt.2010.24. Epub 2010 Feb 23.
Zotero 插件